0001193125-26-186939.txt : 20260428 0001193125-26-186939.hdr.sgml : 20260428 20260428160614 ACCESSION NUMBER: 0001193125-26-186939 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20260428 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260428 DATE AS OF CHANGE: 20260428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPKO HEALTH, INC. CENTRAL INDEX KEY: 0000944809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 752402409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33528 FILM NUMBER: 26907628 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 305-575-4181 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: Opko Health, Inc. DATE OF NAME CHANGE: 20070621 FORMER COMPANY: FORMER CONFORMED NAME: eXegenics Inc DATE OF NAME CHANGE: 20040505 FORMER COMPANY: FORMER CONFORMED NAME: EXEGENICS INC DATE OF NAME CHANGE: 20011114 8-K 1 opk-20260428.htm 8-K 8-K
0000944809false00009448092026-04-282026-04-28

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2026

 

 

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33528

75-2402409

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4400 Biscayne Blvd.

 

Miami, Florida

 

33137

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 305 575-4100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

OPK

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On April 28, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2026. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2026, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release of the Company dated April 28, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By:

/s/ Adam Logal

Date: April 28, 2026

Name:

Adam Logal

Title:

Senior Vice President, Chief Financial Officer

 

 

 

 EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1

img172623995_0.jpg

 

 

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

 

Conference call begins at 4:30 p.m. Eastern time today

 

MIAMI, April 28, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026.

 

Highlights from the first quarter of 2026 and recent weeks included the following:

 

•
Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19.MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers and in immune impaired adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared with conventional monoclonal antibodies. This trial is being funded by the Biomedical Advanced Research and Development Authority (BARDA).

 

•
Initiated MDX2003 Phase 1 clinical trial in relapsed or refractory B-cell lymphoma. MDX2003 (CD19xCD20xCD3xCD28) is a novel tetraspecific T-cell engager-expander designed to optimize sustained T-cell function and address the two most common and validated targets in lymphomas and leukemias. The MDX2003 Phase 1 study (NCT07249905) is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MDX2003 in adults with various types of B-cell lymphoma. The study includes dose-escalation and dose-expansion phases. B-cell lymphoma, a form of non-Hodgkin lymphoma arising from B lymphocytes, represents the most common lymphoma subtype, accounting for approximately 85% of cases.

 

•
ModeX to present data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting with plans to enter Phase 1 studies later this year. Built on its multispecific technology, ModeX recently developed an in vivo CAR‑T and gene delivery platform that it believes is highly differentiated compared with ex vivo and other in vivo CAR‑T approaches. Using antibody‑targeted lipid nanoparticles, this platform can deliver genes encoding chimeric antigen receptors (CARs) directly to specific immune cell subsets that generate functional CAR‑T cells in vivo.

 

•
Presented two posters highlighting MDX2003 and MDX2004 at the ESMO Targeted Anticancer Therapies Congress 2026. In March, an abstract titled “MDX2003, a First-in-Class CD19xCD20xCD3xCD28 Tetraspecific T-Cell Engager with Potent Preclinical Activity against B Cell Malignancies and Promise in Autoimmunity” was presented at the European Society for Medical
Oncology’s (ESMO) Targeted Anticancer Therapies Congress 2026 in Paris. An abstract titled “A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating monotherapy with MDX2004, a trispecific antibody-fusion protein in patients with advanced tumors” was also presented at the Congress.

 

•
Expanded partnership with Entera Bio to advance first-in-class oral long-acting PTH tablet for patients with hypoparathyroidism. This third program under the collaboration combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab® technology. Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2026. OPKO and Entera Bio each hold a 50% ownership interest in the long-acting PTH hypoparathyroidism program and each is responsible for 50% of the program's development costs.

 

First Quarter Financial Results

 

•
Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first quarter of 2026 improved to $51.0 million compared with operating loss of $67.2 million for the 2025 quarter. Net loss for the first quarter of 2026 was $54.8 million, or $0.07 per share, compared with net loss of $67.6 million, or $0.10 per share, for the 2025 quarter. The prior year results included a $3.9 million realized gain from the sale of shares of GeneDx Holdings Corp.

 

•
Pharmaceuticals: Revenue from products in the first quarter of 2026 was $38.0 million compared with $34.8 million in the first quarter of 2025, driven by higher sales volumes from OPKO’s Spanish operations and by a positive net foreign exchange impact of $2.4 million. Revenue from Rayaldee remained consistent at $6.3 million in the first quarter of both 2026 and 2025. Revenue from the transfer of intellectual property and other rose to $14.0 million, up from $12.3 million in 2025. This was highlighted by an increase in gross profit share payments for NGENLA, which totaled $6.4 million compared with $4.5 million in the 2025 quarter. The increase was partially offset by a decrease in revenue recognized under the BARDA contract, which totaled $4.1 million in the first quarter of 2026 compared with $7.0 million for the same period in 2025. Total costs and expenses were $81.7 million in the first quarter of 2026 compared with $81.9 million in the prior-year period. Operating loss narrowed by 15% to $29.7 million in the first quarter of 2026, which included $18.3 million in depreciation and amortization expense, compared with operating loss of $34.8 million in the first quarter of 2025, which included $17.8 million of depreciation and amortization expense.

 

•
Diagnostics: Revenue from services in the first quarter of 2026 was $72.2 million compared with $102.8 million in the prior-year period, which included $25.9 million of revenue related to the oncology assets sold to Labcorp in September 2025. The remaining decrease was principally a result of lower clinical test reimbursement rates as a result of exiting certain higher priced, but lower or negative gross margin test offerings, as well as a slight decrease in overall testing volumes. Total costs and expenses were $85.1 million in the first quarter of 2026 compared with $126.8 million in the first quarter of 2025, which included $31.3 million of costs and expenses related to oncology assets that were sold to Labcorp. Operating loss narrowed by more than 45% to $13.0 million in the first quarter of 2026, which included $3.9 million of depreciation and
amortization expense, compared with operating loss of $23.9 million in the 2025 period, which included $5.7 million of depreciation and amortization expense.

 

•
Cash, cash equivalents, marketable securities and restricted cash: Cash, cash equivalents, marketable securities and restricted cash were $341.9 million as of March 31, 2026. As of March 31, 2026, approximately $92.0 million of OPKO’s common stock had been repurchased under the program since its authorization in July 2025, including $4.8 million in the first quarter of 2026. Approximately $108.0 million remained authorized and available for future repurchases.

 

Financial Guidance

 

The table below contains financial guidance for the 2026 second quarter and the unchanged full year financial guidance (in millions):

 

 

For the three months ended June 30, 2026

 

For the year ended December 31, 2026

 

Low

 

High

 

Low

 

High

Revenue:

 

 

 

 

 

 

 

  Services revenue

$ 72

 

$ 76

 

$ 300

 

$ 312

  Product revenue

38

 

42

 

160

 

170

  IP and other revenue

15

 

19

 

70

 

80

    Total revenue

127

 

132

 

530

 

560

 

 

 

 

 

 

 

 

Included in revenue

 

 

 

 

 

 

 

  Pfizer gross profit share

6

 

8

 

34

 

37

  BARDA

5

 

7

 

18

 

22

 

 

 

 

 

 

 

 

Total costs and expenses

180

 

190

 

725

 

750

R&D included in costs and expenses

32

 

38

 

125

 

135

Conference Call and Webcast Information

 

OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call here. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

 

A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2140261. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

 

About OPKO Health

 

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, please visit www.opko.com.

 

Cautionary Statement Regarding Forward Looking Statements

 

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, including whether and when we will complete the clinical studies initiated for each of MDX2301 and MDX2003, and whether final study data will be positive for one or both studies, whether data will support marketing approval, our ability to develop and commercialize each of MDX2301 and MDX2003, whether MDX2301 is capable of effectively preventing COVID-19, whether each of MDX2301 and MDX2003 will be safe and tolerable, or have any impact on the severity of disease, expectations regarding the products, their efficacy and market potential, whether the in vivo CAR‑T and gene delivery platform is highly differentiated and whether we will initiate a Phase 1 trial in connection therewith, whether we will be able to submit Investigational New Drug application for the oral long-acting PTH tablet and the timing of that submission, whether our expanded collaboration with Entera will be successful, whether our product development efforts will be successful and whether the expected benefits of our products will be realized, including whether preclinical data will be indicative of clinical data should any of our preclinical programs progress into clinical development, whether the relationship with our commercial and strategic partners will be successful, whether our commercial and strategic partners will be able to commercialize our products and successfully utilize our technologies, whether we will continue to successfully advance products in our pipeline and whether they can be commercialized, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

 

Contacts:

Alliance Advisors IR

Yvonne Briggs, 310-691-7100

ybriggs@allianceadvisors.com

or

Bruce Voss, 310-691-7100

bvoss@allianceadvisors.com

 

—Tables to Follow—

 

OPKO Health, Inc. and Subsidiaries

Summary of Revenues

(in millions)

Unaudited

 

 

 

 

 

 

 

 

 

 

 

For the three months ended March 31,

 

 

 

 

 

 

 

 

 

2026

 

2025

Diagnostics revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

Core diagnostics

 

 

 

 

 

 

 

 

$

65.8

 

$

70.4

4Kscore Test

 

 

 

 

 

 

 

 

 

6.4

 

 

6.5

Divested revenue

 

 

 

 

 

 

 

 

 

0.0

 

 

25.9

Revenue from services

 

 

 

 

 

 

 

 

 

72.2

 

 

102.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

International operations

 

 

 

 

 

 

 

 

 

31.7

 

 

28.5

Rayaldee

 

 

 

 

 

 

 

 

 

6.3

 

 

6.3

Revenue from products subtotal

 

 

 

 

 

 

 

 

 

38.0

 

 

34.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NGENLA royalty and profit sharing, and cost sharing

 

 

 

 

 

 

 

 

 

6.4

 

 

4.5

BARDA

 

 

 

 

 

 

 

 

 

4.1

 

 

7.0

Regeneron

 

 

 

 

 

 

 

 

 

0.9

 

 

-

Other royalties and milestones

 

 

 

 

 

 

 

 

 

2.6

 

 

0.8

Revenue from transfer of intellectual property and other subtotal

 

 

 

 

 

 

 

 

 

14.0

 

 

12.3

Total pharmaceutical revenue

 

 

 

 

 

 

 

 

 

52.0

 

 

47.1

Total revenues

 

 

 

 

 

 

 

 

$

124.2

 

$

149.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPKO Health, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in millions)

Unaudited

 

 

 

As of

 

March 31,

2026

 

December 31,

2025

Assets:

 

 

 

 

 

 

 

Cash, cash equivalents, and current restricted cash

$

341.9

 

 

$

369.1

 

Accounts receivable, net

 

79.6

 

 

 

90.3

 

Inventory, net

 

64.4

 

 

 

65.8

 

Other current assets

 

49.4

 

 

 

56.7

 

Total current assets

 

535.3

 

 

 

581.9

 

In-process research and development and goodwill

 

677.3

 

 

 

679.3

 

Other assets

 

644.2

 

 

 

670.7

 

Total Assets

$

1,856.8

 

 

$

1,931.9

 

 

 

 

 

 

 

 

 

Liabilities and Equity:

 

 

 

 

 

 

 

Accounts payable

$

44.2

 

 

$

41.1

 

Accrued expenses

 

83.5

 

 

 

84.4

 

Other current liabilities

 

20.7

 

 

 

21.1

 

Total current liabilities

 

148.4

 

 

 

146.6

 

Long-term portion of convertible notes

 

87.4

 

 

 

85.0

 

Senior secured royalty financing

 

246.6

 

 

 

246.4

 

Deferred tax liabilities, net

 

114.6

 

 

 

126.3

 

Other long-term liabilities, principally leases,

and lines of credit

 

 

55.2

 

 

 

 

59.6

 

Total Liabilities

 

652.2

 

 

 

663.9

 

Equity

 

1,204.6

 

 

 

1,268.0

 

Total Liabilities and Equity

$

1,856.8

 

 

$

1,931.9

 

 

 

 

 

 

 

 

 

 

 

OPKO Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in millions, except share and per share data)

Unaudited

 

 

 

For the three months ended

March 31,

 

 

 

2026

 

 

 

2025

 

Revenues

 

 

 

 

 

 

 

 

Revenue from services

 

$

72.2

 

 

$

102.8

 

Revenue from products

 

 

38.0

 

 

 

34.8

 

Revenue from transfer of intellectual property

 

 

14.0

 

 

 

12.3

 

Total revenues

 

 

124.2

 

 

 

149.9

 

Costs and expenses

 

 

 

 

 

 

 

 

Cost of service revenues

 

 

56.1

 

 

 

84.5

 

Cost of product revenues

 

 

22.3

 

 

 

22.8

 

Selling, general and administrative

 

 

48.6

 

 

 

59.1

 

Research and development

 

 

29.2

 

 

 

30.8

 

Amortization of intangible assets

 

 

19.0

 

 

 

19.9

 

Total costs and expenses

 

 

175.2

 

 

 

217.1

 

Operating loss

 

 

(51.0

)

 

 

(67.2

)

Other expense, net

 

 

(9.9

)

 

 

(6.2

)

Loss before income taxes and investment losses

 

 

(60.9

)

 

 

(73.4

)

Income tax benefit

 

 

6.1

 

 

 

5.8

 

Net loss before investment losses

 

 

(54.8

)

 

 

(67.6

)

Loss from investments in investees

 

 

(0.0

)

 

 

(0.0

)

Net loss

 

$

(54.8

)

 

$

(67.6

)

Loss per share, basic and diluted

 

$

(0.07

)

 

$

(0.10

)

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

758,876,415

 

 

 

671,577,429

 

 

 

 

# # #

 

 GRAPHIC 3 img172623995_0.jpg GRAPHIC begin 644 img172623995_0.jpg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opk-20260428.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document And Entity Information
Apr. 28, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 28, 2026
Entity Registrant Name OPKO Health, Inc.
Entity Central Index Key 0000944809
Entity Emerging Growth Company false
Entity File Number 001-33528
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 75-2402409
Entity Address, Address Line One 4400 Biscayne Blvd.
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33137
City Area Code 305
Local Phone Number 575-4100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OPK
Security Exchange Name NASDAQ
XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports opk-20260428.htm opk-20260428.xsd http://xbrl.sec.gov/dei/2025 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "opk-20260428.htm": { "nsprefix": "opk", "nsuri": "http://opko.com/20260428", "dts": { "inline": { "local": [ "opk-20260428.htm" ] }, "schema": { "local": [ "opk-20260428.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 22 }, "report": { "R1": { "role": "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_0066f921-798a-4cbd-b060-918d13dfde77", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk-20260428.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0066f921-798a-4cbd-b060-918d13dfde77", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk-20260428.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://opko.com/20260428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0001193125-26-186939-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-26-186939-xbrl.zip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opk-20260428_htm.xml IDEA: XBRL DOCUMENT 0000944809 2026-04-28 2026-04-28 0000944809 false 8-K 2026-04-28 OPKO Health, Inc. DE 001-33528 75-2402409 4400 Biscayne Blvd. Miami FL 33137 305 575-4100 false false false false Common Stock OPK NASDAQ false